Close

Innovate Biopharma (INNT) Commences First Phase 3 Clinical Trial in Celiac Disease

June 10, 2019 8:04 AM EDT

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced the start of the first phase 3 clinical trial in celiac disease. Innovate expects to provide further updates as screening and enrollment proceed over the next few months.

Innovate’s Chief Medical Officer, Dr. Patrick H. Griffin, stated, “We are proud to start the first ever phase 3 clinical trial to address a large unmet need for celiac patient suffering from continued symptoms in spite of being on a gluten-free diet.” Innovate’s Chairman and CEO, Dr. Sandeep Laumas, added, “This is a landmark event in the history of celiac disease for the first ever phase 3 trial to get underway as well as a key pivotal moment for Innovate. We are especially thankful to our partners, physicians and our investors whose support of Innovate’s management has led to this outcome.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Management Comments

Related Entities

Earnings